10x Genomics Inc has a consensus price target of $50.94, established from looking at the 40 latest analyst ratings. The last 3 analyst ratings were released from Deutsche Bank, Barclays, and Stifel on April 18, 2024, April 10, 2024, and February 16, 2024. With an average price target of $54.33 between Deutsche Bank, Barclays, and Stifel, there's an implied 101.98% upside for 10x Genomics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
04/18/2024 | TXG | Buy Now | 10x Genomics | $26.90 | 104.46% | Deutsche Bank | Justin Bowers | $60 → $55 | Maintains | Buy | Get Alert |
04/10/2024 | TXG | Buy Now | 10x Genomics | $26.90 | 67.29% | Barclays | Luke Sergott | $55 → $45 | Maintains | Overweight | Get Alert |
02/16/2024 | TXG | Buy Now | 10x Genomics | $26.90 | 134.2% | Stifel | Daniel Arias | $68 → $63 | Maintains | Buy | Get Alert |
01/25/2024 | TXG | Buy Now | 10x Genomics | $26.90 | 104.46% | Barclays | Luke Sergott | $45 → $55 | Maintains | Overweight | Get Alert |
12/14/2023 | TXG | Buy Now | 10x Genomics | $26.90 | 123.05% | Guggenheim | Subbu Nambi | → $60 | Initiates | → Buy | Get Alert |
12/13/2023 | TXG | Buy Now | 10x Genomics | $26.90 | — | Wolfe Research | Doug Schenkel | — | Initiates | → Outperform | Get Alert |
12/12/2023 | TXG | Buy Now | 10x Genomics | $26.90 | 100.74% | B of A Securities | Derik De Bruin | $36 → $54 | Upgrade | Underperform → Neutral | Get Alert |
09/29/2023 | TXG | Buy Now | 10x Genomics | $26.90 | 74.72% | Barclays | Luke Sergott | $66 → $47 | Maintains | Overweight | Get Alert |
09/19/2023 | TXG | Buy Now | 10x Genomics | $26.90 | 160.22% | Canaccord Genuity | Kyle Mikson | → $70 | Reiterates | Buy → Buy | Get Alert |
08/07/2023 | TXG | Buy Now | 10x Genomics | $26.90 | 141.64% | Morgan Stanley | Tejas Savant | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
08/04/2023 | TXG | Buy Now | 10x Genomics | $26.90 | 145.35% | Barclays | Luke Sergott | $65 → $66 | Maintains | Overweight | Get Alert |
08/04/2023 | TXG | Buy Now | 10x Genomics | $26.90 | 178.81% | Citigroup | Patrick Donnelly | $65 → $75 | Maintains | Buy | Get Alert |
07/13/2023 | TXG | Buy Now | 10x Genomics | $26.90 | 11.52% | Goldman Sachs | Matthew Sykes | $25 → $30 | Maintains | Sell | Get Alert |
05/18/2023 | TXG | Buy Now | 10x Genomics | $26.90 | 141.64% | Stephens & Co. | Mason Carrico | → $65 | Reiterates | Overweight → Overweight | Get Alert |
05/10/2023 | TXG | Buy Now | 10x Genomics | $26.90 | 141.64% | Barclays | Luke Sergott | → $65 | Initiates | → Overweight | Get Alert |
05/04/2023 | TXG | Buy Now | 10x Genomics | $26.90 | 152.79% | Stifel | Daniel Arias | $57 → $68 | Maintains | Buy | Get Alert |
05/04/2023 | TXG | Buy Now | 10x Genomics | $26.90 | 145.35% | TD Cowen | Dan Brennan | $62 → $66 | Maintains | Outperform | Get Alert |
05/04/2023 | TXG | Buy Now | 10x Genomics | $26.90 | 141.64% | Canaccord Genuity | Kyle Mikson | $58 → $65 | Maintains | Buy | Get Alert |
05/04/2023 | TXG | Buy Now | 10x Genomics | $26.90 | 141.64% | Stephens & Co. | Mason Carrico | → $65 | Reiterates | → Overweight | Get Alert |
The latest price target for 10x Genomics (NASDAQ: TXG) was reported by Deutsche Bank on April 18, 2024. The analyst firm set a price target for $55.00 expecting TXG to rise to within 12 months (a possible 104.46% upside). 19 analyst firms have reported ratings in the last year.
The latest analyst rating for 10x Genomics (NASDAQ: TXG) was provided by Deutsche Bank, and 10x Genomics maintained their buy rating.
The last upgrade for 10x Genomics Inc happened on December 12, 2023 when B of A Securities raised their price target to $54. B of A Securities previously had an underperform for 10x Genomics Inc.
The last downgrade for 10x Genomics Inc happened on August 18, 2022 when Goldman Sachs changed their price target from $55 to $35 for 10x Genomics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 10x Genomics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 10x Genomics was filed on April 18, 2024 so you should expect the next rating to be made available sometime around April 18, 2025.
While ratings are subjective and will change, the latest 10x Genomics (TXG) rating was a maintained with a price target of $60.00 to $55.00. The current price 10x Genomics (TXG) is trading at is $26.90, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.